This document summarizes research on using antibody-protamine fusions to deliver small interfering RNA (siRNA) to target cells via cell surface receptors. The fusion efficiently binds siRNA and delivers it to HIV envelope or cancer cells expressing the target receptor. This allows for gene silencing in these target cells. Results showed silencing of HIV gag gene and inhibition of tumor cell proliferation through delivery of siRNAs against c-myc, MDM2, and VEGF genes. Specificity was achieved as gene silencing only occurred in cells expressing the target receptor.